A detailed history of Amalgamated Bank transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Amalgamated Bank holds 9,617 shares of COLL stock, worth $316,495. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,617
Previous 10,035 4.17%
Holding current value
$316,495
Previous $323,000 15.17%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$31.4 - $39.07 $13,125 - $16,331
-418 Reduced 4.17%
9,617 $372,000
Q2 2024

Aug 12, 2024

SELL
$31.36 - $39.99 $1,505 - $1,919
-48 Reduced 0.48%
10,035 $323,000
Q1 2024

Apr 23, 2024

SELL
$31.23 - $40.91 $118,268 - $154,926
-3,787 Reduced 27.3%
10,083 $391,000
Q4 2023

Feb 06, 2024

SELL
$21.16 - $30.8 $44,457 - $64,710
-2,101 Reduced 13.16%
13,870 $427,000
Q3 2023

Nov 08, 2023

BUY
$21.23 - $24.28 $3,821 - $4,370
180 Added 1.14%
15,971 $357,000
Q2 2023

Aug 11, 2023

BUY
$21.06 - $24.0 $10,719 - $12,216
509 Added 3.33%
15,791 $339,000
Q1 2023

May 02, 2023

SELL
$23.0 - $29.88 $25,001 - $32,479
-1,087 Reduced 6.64%
15,282 $367,000
Q4 2022

Feb 10, 2023

SELL
$16.14 - $23.55 $2,824 - $4,121
-175 Reduced 1.06%
16,369 $380,000
Q3 2022

Nov 09, 2022

BUY
$15.46 - $20.1 $2,257 - $2,934
146 Added 0.89%
16,544 $265,000
Q2 2022

Aug 15, 2022

SELL
$14.22 - $20.88 $6,413 - $9,416
-451 Reduced 2.68%
16,398 $291,000
Q1 2022

Jun 30, 2022

SELL
$17.2 - $22.5 $18,885 - $24,705
-1,098 Reduced 6.12%
16,849 $343,000
Q4 2021

Feb 15, 2022

SELL
$17.5 - $21.35 $11,725 - $14,304
-670 Reduced 3.6%
17,947 $335,000
Q3 2021

Oct 29, 2021

SELL
$17.75 - $25.39 $5,609 - $8,023
-316 Reduced 1.67%
18,617 $367,000
Q2 2021

Aug 16, 2021

BUY
$21.74 - $25.28 $411,603 - $478,626
18,933 New
18,933 $448,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.12B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.